Home / Therapeutic Area / Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

Published: Nov 2017 | Published By: GBI Research

Description

This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.

Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary

3 Introduction
3.1 Gastric and Esophageal Cancer Report Coverage
3.2 Esophageal Cancer – Overview
3.3 Gastric Cancer – Overview
3.4 GBI Research Report Guidance

4 Therapeutics Development
4.1 Esophageal Cancer
4.1.1 Pipeline Overview
4.1.2 Pipeline by Companies
4.1.3 Pipeline by Universities/Institutes
4.1.4 Products under Development by Companies
4.1.5 Products under Development by Universities/Institutes
4.2 Gastric Cancer
4.2.1 Pipeline Overview
4.2.2 Pipeline by Companies
4.2.3 Pipeline by Universities/Institutes
4.2.4 Products under Development by Companies
4.2.5 Products under Development by Universities/Institutes

5 Therapeutics Assessment
5.1 Esophageal Cancer
5.1.1 Assessment by Target
5.1.2 Assessment by Mechanism of Action
5.1.3 Assessment by Route of Administration
5.1.4 Assessment by Molecule Type
5.2 Gastric Cancer
5.2.1 Assessment by Target
5.2.2 Assessment by Mechanism of Action
5.2.3 Assessment by Route of Administration
5.2.4 Assessment by Molecule Type

6 Companies Involved in Therapeutics Development
6.1 Esophageal Cancer
6.1.1 Adaptimmune Therapeutics Plc
6.1.2 ADC Therapeutics Sarl
6.1.3 Aduro BioTech Inc
6.1.4 Advenchen Laboratories LLC
6.1.5 Almac Discovery Ltd
6.1.6 Ambrx Inc
6.1.7 Amgen Inc
6.1.8 Aprea AB
6.1.9 ArQule Inc
6.1.10 Array BioPharma Inc
6.1.11 Aslan Pharmaceuticals Pte Ltd
6.1.12 Bayer AG
6.1.13 BeiGene Ltd
6.1.14 BioStar Pharmaceuticals Inc
6.1.15 Boehringer Ingelheim GmbH
6.1.16 Bristol-Myers Squibb Co
6.1.17 Cascadian Therapeutics Inc
6.1.18 CBT Pharmaceuticals Inc
6.1.19 Celgene Corp
6.1.20 Celldex Therapeutics Inc
6.1.21 Cellectar Biosciences Inc
6.1.22 Clovis Oncology Inc
6.1.23 Cyclacel Pharmaceuticals Inc
6.1.24 DAE HWA Pharmaceutical Co Ltd
6.1.25 Eli Lilly and Co
6.1.26 F. Hoffmann-La Roche Ltd
6.1.27 Genmab A/S
6.1.28 GlaxoSmithKline Plc
6.1.29 Glycotope GmbH
6.1.30 Hanmi Pharmaceuticals Co Ltd
6.1.31 Hutchison MediPharma Ltd
6.1.32 Ignyta Inc
6.1.33 Immunocore Ltd
6.1.34 ImmunoFrontier Inc
6.1.35 Immunomedics Inc
6.1.36 Incyte Corp
6.1.37 Jiangsu Hengrui Medicine Co Ltd
6.1.38 Johnson & Johnson
6.1.39 Leap Therapeutics Inc
6.1.40 Madrigal Pharmaceuticals Inc.
6.1.41 MaxiVAX SA
6.1.42 Mebiopharm Co Ltd
6.1.43 MedImmune LLC
6.1.44 Merck & Co Inc
6.1.45 Merrimack Pharmaceuticals Inc
6.1.46 Novartis AG
6.1.47 Omeros Corp
6.1.48 Omnitura Therapeutics Inc
6.1.49 Oncolys BioPharma Inc
6.1.50 Ono Pharmaceutical Co Ltd
6.1.51 Puma Biotechnology Inc
6.1.52 Rhizen Pharmaceuticals SA
6.1.53 Shionogi & Co Ltd
6.1.54 Spectrum Pharmaceuticals Inc
6.1.55 Steba Biotech SA
6.1.56 Stelic Institute & Co Inc
6.1.57 Supratek Pharma Inc
6.1.58 Symphogen A/S
6.1.59 Taiho Pharmaceutical Co Ltd
6.1.60 Taiwan Liposome Company Ltd
6.1.61 Takara Bio Inc
6.1.62 Transgene Biotek Ltd
6.1.63 XuanZhu Pharma Co Ltd
6.2 Gastric Cancer
6.2.1 3SBio Inc
6.2.2 AbbVie Inc
6.2.3 AbGenomics International Inc
6.2.4 Abion Inc
6.2.5 Adaptimmune Therapeutics Plc
6.2.6 ADC Therapeutics Sarl
6.2.7 Aduro BioTech Inc
6.2.8 Advenchen Laboratories LLC
6.2.9 Allist Shanghai Pharmaceutical Technology Co Ltd
6.2.10 Almac Discovery Ltd
6.2.11 Alteogen Inc
6.2.12 Ambrx Inc
6.2.13 amcure GmbH
6.2.14 Amgen Inc
6.2.15 ANP Technologies Inc
6.2.16 Antikor Biopharma Ltd
6.2.17 arGEN-X BV
6.2.18 Array BioPharma Inc
6.2.19 Asana BioSciences LLC
6.2.20 Aslan Pharmaceuticals Pte Ltd
6.2.21 Astellas Pharma Inc
6.2.22 AstraZeneca Plc
6.2.23 Athenex Inc
6.2.24 Basilea Pharmaceutica Ltd
6.2.25 Bayer AG
6.2.26 BeiGene Ltd
6.2.27 Beijing Hanmi Pharmaceutical Co Ltd
6.2.28 Betta Pharmaceuticals Co Ltd
6.2.29 Biocon Ltd
6.2.30 Bioleaders Corp
6.2.31 Bionovis SA
6.2.32 Boehringer Ingelheim GmbH
6.2.33 Bristol-Myers Squibb Co
6.2.34 Camel-IDS NV
6.2.35 Cancer Prevention Pharmaceuticals Inc
6.2.36 Cascadian Therapeutics Inc
6.2.37 CBT Pharmaceuticals Inc
6.2.38 Celgene Corp
6.2.39 Celldex Therapeutics Inc
6.2.40 Cellectar Biosciences Inc
6.2.41 Celltrion Inc
6.2.42 Celon Pharma SA
6.2.43 Chipscreen Biosciences Ltd
6.2.44 Chugai Pharmaceutical Co Ltd
6.2.45 Curaxys SL
6.2.46 Cytori Therapeutics Inc
6.2.47 Daiichi Sankyo Co Ltd
6.2.48 Debiopharm International SA
6.2.49 Deciphera Pharmaceuticals LLC
6.2.50 Dr. Reddy's Laboratories Ltd
6.2.51 Eddingpharm Inc
6.2.52 Eli Lilly and Co
6.2.53 EOS Biosciences Inc
6.2.54 Erytech Pharma SA
6.2.55 Esperance Pharmaceuticals Inc
6.2.56 Exelixis Inc
6.2.57 F-star Biotechnology Ltd
6.2.58 F. Hoffmann-La Roche Ltd
6.2.59 Five Prime Therapeutics Inc
6.2.60 Frost Biologic Inc
6.2.61 Galena Biopharma Inc
6.2.62 Genelux Corp
6.2.63 Genentech Inc
6.2.64 Gilead Sciences Inc
6.2.65 GlaxoSmithKline Plc
6.2.66 Glenmark Pharmaceuticals Ltd
6.2.67 GlycoNex Inc
6.2.68 Glycotope GmbH
6.2.69 Green Cross Corp
6.2.70 Halozyme Therapeutics Inc
6.2.71 Hanmi Pharmaceuticals Co Ltd
6.2.72 Horizon Pharma Plc
6.2.73 Humanigen Inc
6.2.74 Hummingbird Bioscience Pte Ltd
6.2.75 Hutchison MediPharma Ltd
6.2.76 Ignyta Inc
6.2.77 Ildong Pharmaceutical Co Ltd
6.2.78 Immunomedics Inc
6.2.79 Incyte Corp
6.2.80 Inovio Pharmaceuticals Inc
6.2.81 Inspyr Therapeutics Inc
6.2.82 Insys Therapeutics Inc
6.2.83 Ipsen SA
6.2.84 Jiangsu Hengrui Medicine Co Ltd
6.2.85 Jiangsu Kanion Pharmaceutical Co Ltd
6.2.86 Johnson & Johnson
6.2.87 Jounce Therapeutics Inc
6.2.88 Konruns Pharmaceutical Co Ltd
6.2.89 Kringle Pharma Inc
6.2.90 Kuhnil Pharmaceutical Co Ltd
6.2.91 Kyowa Hakko Kirin Co Ltd
6.2.92 LATITUDE Pharmaceuticals Inc
6.2.93 LegoChem Biosciences Inc
6.2.94 LinXis BV
6.2.95 MacroGenics Inc
6.2.96 Madrigal Pharmaceuticals Inc.
6.2.97 MaxiVAX SA
6.2.98 Mebiopharm Co Ltd
6.2.99 MedImmune LLC
6.2.100 Merck & Co Inc
6.2.101 Merck KGaA
6.2.102 Merrimack Pharmaceuticals Inc
6.2.103 Mersana Therapeutics Inc
6.2.104 Merus NV
6.2.105 Mirati Therapeutics Inc
6.2.106 Molecular Partners AG
6.2.107 Molecular Targeting Technologies Inc
6.2.108 Moleculin Biotech Inc
6.2.109 MolMed SpA
6.2.110 NanoCarrier Co Ltd
6.2.111 Novartis AG
6.2.112 Novogen Ltd
6.2.113 OBI Pharma Inc
6.2.114 Oncobiologics Inc
6.2.115 Oncolys BioPharma Inc
6.2.116 OncoMed Pharmaceuticals Inc
6.2.117 OncoResponse Inc
6.2.118 Ono Pharmaceutical Co Ltd
6.2.119 Opsona Therapeutics Ltd
6.2.120 Patrys Ltd
6.2.121 Pfizer Inc
6.2.122 Pharma Mar SA
6.2.123 Pieris Pharmaceuticals Inc
6.2.124 Plexxikon Inc
6.2.125 Prescient Therapeutics Ltd
6.2.126 Puma Biotechnology Inc
6.2.127 Redx Pharma Plc
6.2.128 Rhizen Pharmaceuticals SA
6.2.129 Richter Gedeon Nyrt
6.2.130 Samumed LLC
6.2.131 Sanofi
6.2.132 Selecta Biosciences Inc
6.2.133 Sequella Inc
6.2.134 Shionogi & Co Ltd
6.2.135 Simcere Pharmaceutical Group
6.2.136 Sorrento Therapeutics Inc
6.2.137 Spectrum Pharmaceuticals Inc
6.2.138 Stelic Institute & Co Inc
6.2.139 Supratek Pharma Inc
6.2.140 SynCore Biotechnology Co Ltd
6.2.141 Synovo GmbH
6.2.142 Synthon Holdings BV
6.2.143 Taiho Pharmaceutical Co Ltd
6.2.144 Taiwan Liposome Company Ltd
6.2.145 Takis Srl
6.2.146 Tessa Therapeutics Pte Ltd
6.2.147 Transgene SA
6.2.148 Tyrogenex Inc
6.2.149 United BioPharma Inc
6.2.150 Vaxon Biotech
6.2.151 ViiV Healthcare Ltd
6.2.152 Viracta Therapeutics Inc
6.2.153 XuanZhu Pharma Co Ltd
6.2.154 Zymeworks Inc

7 Dormant Projects
7.1 Esophageal Cancer
7.2 Gastric Cancer

8 Discontinued Products
8.1 Esophageal Cancer
8.2 Gastric Cancer

9 Product Development Milestones
9.1 Esophageal Cancer
9.1.1 Featured News & Press Releases
9.2 Gastric Cancer
9.2.1 Featured News & Press Releases

10 Appendix
10.1 Methodology
10.2 Coverage
10.3 Secondary Research
10.4 Primary Research
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +